Summaries of the Section H (HML) update

Each month we issue a summary of the HML update. The table on this page gives a preview of the upcoming changes.

The table on this page gives a preview of the upcoming changes that will be announced in next month’s Section H of the Pharmaceutical Schedule.

The changes will be published in the Online HML(external link) around the 23^rd of this month and are effective from next month.

For any questions about these listing changes or the Pharmaceutical Schedule in general, email us at enquiry@pharmac.govt.nz.

16 October 2026 - preview of changes for November 2026

Pharmaceutical	Change
Abacavir sulphate tab 300 mg (Ziagen) and oral liq 20 mg per ml	removal of restriction criteria
Abacavir sulphate with lamivudine (Abacavir/lamivudine Viatris) tab 600 mg with lamivudine 300 mg	removal of restriction criteria
Adalimumab (Amgevita) inj 20 mg per 0.4 ml prefilled syringe, inj 40 mg per 0.8 ml prefilled pen and inj 40 mg per 0.8 ml prefilled syringe	amended restriction criteria
Adalimumab (Humira - Alternative Brand) inj 20 mg per 0.2 ml prefilled syringe and inj 40 mg per 0.4 ml prefilled syringe (Humira) and inj 40 mg per 0.4 ml prefilled pen (HumiraPen)	amended restriction criteria
Antiretrovirals	addition of note
Aspirin (Ethics Aspirin) tab dispersible 300 mg	price increase and addition of PSS
Atazanavir sulphate (Atazanavir Viatris) cap 150 mg and cap 200 mg	removal of restriction criteria
Bedaquiline (Sirturo) tab 100 mg	amended restriction criteria
Calcitriol (Calcitriol Devatis) cap 0.25 mcg and cap 0.5 mcg	PSS start date delayed
Calcitriol (Calcitriol XL and Calcitriol-AFT) cap 0.25 mcg and cap 0.5 mcg	delisting delayed
Captopril (DP-Captopril) oral liq 5 mg per ml, 100 ml	amended restriction criteria
Ceftolozane with tazobactam (Zerbaxa) inj 1,000 mg with tazobactam 500 mg, 20 ml vial	new listing (p’code 2633841)
Cetirizine hydrochloride oral liq 1 mg per ml	Brand change Noumed Cetirizine Hayfever & Allergy Relief – new listing and addition of PSS (p’code 2739933) Histaclear to be delisted 1 April 2027
Citric acid with magnesium oxide and sodium picosulfate (e.g. Picosalax) powder for oral soln 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet	new listing
Darunavir (Darunavir Viatris) tab 400 mg and tab 600 mg	removal of restriction criteria
Dolutegravir tab dispersible 5 mg	new listing
Dolutegravir tab 50 mg (Tivicay) and tab dispersible 5 mg	removal of restriction criteria
Dolutegravir with lamivudine (Dovato) tab 50 mg with lamivudine 300 mg	removal of restriction criteria
Efavirenz tab 600 mg (Efavirenz Milpharm) and oral liq 30 mg per ml	removal of restriction criteria
Efavirenz with emtricitabine and tenofovir disoproxil tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate) (Viatris) and tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a fumarate) (TEEVIR, TEEVIR (India), Tenofovir Efavirenz Emtricitabine (Mylan))	removal of restriction criteria
Emtricitabine (Emtriva) cap 200 mg	removal of restriction criteria
Emtricitabine with tenofovir disoproxil tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate) (Tenofovir Disoproxil Emtricitabine Viatr) and tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a fumarate) (Tenofovir Disoproxil Emtricitabine Mylan)	removal of restriction criteria
Etravirine (Intelence) tab 200 mg	removal of restriction criteria
Flecainide acetate (Almarytm and Tambocor German) inj 10 mg per ml, 15 ml ampoule	delisted 1 November 2026
Fluconazole (APO Fluconazole) cap 200 mg	new listing (p’code 2735024)
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] (Gardasil 9) inj 270 mcg in 0.5 ml syringe	amended restriction criteria
Hydrocortisone acetate (Cortifoam) rectal foam 10%, CFC free (14 applications)	new listing (p’code 2608707)
Ibrutinib (Imbruvica) tab 140 mg and tab 420 mg	amended restriction criteria
Ibuprofen (Ibuprofen-AFT) tab 200 mg - 20 tablet pack	new listing and addition of PSS (p’code 2697106)
Imatinib mesilate (Imatinib-Rex) cap 100 mg and cap 400 mg	price decrease and addition of PSS
Indinavir cap 200 mg and cap 400 mg	removal of restriction criteria
Insulin aspart with insulin aspart protamine (NovoMix 30 FlexPen) inj insulin aspart 30% with insulin aspart protamine 70%, 100 u per ml, 3 ml prefilled pen	to be delisted 1 July 2027
Ipilimumab (Yervoy) inj 5 mg per ml, 10 ml vial and inj 5 mg per ml, 40 ml vial	amended restriction criteria
Lamivudine tab 150 mg (Lamivudine Viatris) and oral liq 10 mg per ml	removal of restriction criteria
Lidocaine [lignocaine] hydrochloride with adrenaline and tetracaine hydrochloride (Laceraine) gel 4% with 0.18% adrenaline and 0.5% tetracaine, 4 ml vial	price increase
Lopinavir with ritonavir Tab 100 mg with ritonavir 25 mg Tab 200 mg with ritonavir 50 mg (Lopinavir/Ritonavir Mylan) Oral liq 80 mg per ml with ritonavir 20 mg per ml	removal of restriction criteria
Methotrexate (Methotrexate Ebewe) inj 100 mg per ml, 50 ml vial	price increase and addition of PSS
Morphine hydrochloride (RA-Morph) oral liq 2 mg per ml and oral liq 5 mg per ml	price increase and addition of PSS
Naltrexone hydrochloride tab 50 mg	Brand change Naltrexone Lupin – new listing and addition of PSS (p’code 2733307) Naltraccord to be delisted 1 April 2027
Nevirapine (Viramune Suspension) oral suspension 10 mg per ml	delisted 1 November 2026
Nevirapine tab 200 mg (Nevirapine Viatris) and oral suspension 10 mg per ml	amended restriction criteria
Nivolumab (Opdivo) inj 10 mg per ml, 4 ml vial and inj 10 mg per ml, 10 ml vial	amended restriction criteria
Non-Nucleoside Reverse Transcriptase Inhibitors	removal of restriction criteria
Nucleoside Reverse Transcriptase Inhibitors	removal of restriction criteria
Oral feed 1.5 kcal/ml (Fortijuce (Apple), Fortijuce (Orange) and Fortijuce (Strawberry)) liquid 4 g protein and 33.5 g carbohydrate per 100 ml, 200 ml bottle	amended brand name
Pioglitazone (Rising)	new listing Tab 15 mg (p’code 2739917) Tab 30 mg (p’code 2739925)
Protease Inhibitors	removal of restriction criteria
Raltegravir potassium grans for oral liq 100 mg	new listing
Raltegravir potassium tab 400 mg (Isentress) and tab 600 mg (Isentress HD) and grans for oral liq 100 mg	removal of restriction criteria
Riboflavin tab 100 mg and cap 100 mg	amended restriction criteria
Ritonavir (Norvir) tab 100 mg	removal of restriction criteria
Sildenafil (Sildenafil (Umedica)) tab 50 mg	new listing (p’code 2738805)
Stavudine cap 30 mg, cap 40 mg and powder for oral soln 1 mg per ml	removal of restriction criteria
Strand Transfer Inhibitors	removal of restriction criteria
Tamsulosin hydrochloride (Aurobindo Tamsulosin) cap 400 mcg	delisted 1 November 2026
Teriparatide (Teriparatide Teva) inj 250 mcg per ml, 2.4 ml	amended brand name
Venetoclax (Venclexta) tab 14 × 10 mg, 7 × 50 mg, 21 × 100 mg, tab 10 mg, tab 50 mg and tab 100 mg	amended restriction criteria
Venlafaxine (Venlofex) cap 75 mg	new listing (p’code 2738910)
Zidovudine cap 100 mg and oral liq 10 mg per ml (Retrovir) and inj 10 mg per ml, 20 ml vial (Retrovir IV)	removal of restriction criteria
Zidovudine with lamivudine (Lamivudine/Zidovudine Viatris) tab 300 mg with lamivudine 150 mg	removal of restriction criteria

Changes to General Rules

We have made amendments to Pharmaceutical Schedule Rules to give effect to the Paediatric Oncology Funding Policy from 1 November 2026.

Find previous months' summaries